These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1282 related articles for article (PubMed ID: 31788949)

  • 21. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
    J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios.
    Ankrah DNA; Darko DM; Sabblah G; Mantel-Teeuwisse A; Leufkens HMG
    Hum Vaccin Immunother; 2018 Jan; 14(1):172-178. PubMed ID: 29172941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention.
    Varman M; Sharlin C; Fernandez C; Vasudevan J; Wichman C
    J Community Health; 2018 Jun; 43(3):455-458. PubMed ID: 29368102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papilloma virus vaccination and its real-life efficacy.
    Schroll JB
    Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1267-1268. PubMed ID: 32939761
    [No Abstract]   [Full Text] [Related]  

  • 25. Letter to the Editor: Regarding HPV vaccination in patients who are infected with an oncogenic subtype.
    Griffith RD; Simmons BJ; Falto-Aizpurua L; Nouri K
    Head Neck; 2016 Jan; 38(1):156. PubMed ID: 26563746
    [No Abstract]   [Full Text] [Related]  

  • 26. High HPV vaccination uptake rates for adolescent girls after regional governmental funding in Shiki City, Japan.
    Hayashi Y; Shimizu Y; Netsu S; Hanley S; Konno R
    Vaccine; 2012 Aug; 30(37):5547-50. PubMed ID: 22749837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vaccination: A Double Opportunity to Prevent Human Papilloma Virus Infection].
    Chambel B
    Acta Med Port; 2020 Jun; 33(6):440. PubMed ID: 32504521
    [No Abstract]   [Full Text] [Related]  

  • 28. Suspected adverse effects after human papillomavirus vaccination: a temporal relationship.
    Ikeda SI; Hineno A; Ozawa K; Kinoshita T
    Immunol Res; 2018 Dec; 66(6):723-725. PubMed ID: 30719604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress and challenges for the Japanese immunization program: Beyond the "vaccine gap".
    Saitoh A; Okabe N
    Vaccine; 2018 Jul; 36(30):4582-4588. PubMed ID: 29929825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does human papilloma virus play a role in sinonasal inverted papilloma?
    Govindaraj S; Wang H
    Curr Opin Otolaryngol Head Neck Surg; 2014 Feb; 22(1):47-51. PubMed ID: 24322658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discussing human papilloma virus vaccination.
    Quah YL; Aggarwal IM
    BMJ; 2017 Jun; 357():j2730. PubMed ID: 28642269
    [No Abstract]   [Full Text] [Related]  

  • 33. Human papilloma virus vaccination in Nepal: an initial experience in Nepal.
    Singh Y; Shah A; Singh M; Verma S; Shrestha BM; Vaidya P; Nakarmi RP; Shrestha SB
    Asian Pac J Cancer Prev; 2010; 11(3):615-7. PubMed ID: 21039025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
    Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
    Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Policy on Human Papilloma Virus Vaccinations.
    Pediatr Dent; 2018 Oct; 40(6):82-83. PubMed ID: 32074859
    [No Abstract]   [Full Text] [Related]  

  • 36. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.
    Lin YL; Borenstein LA; Selvakumar R; Ahmed R; Wettstein FO
    Virology; 1992 Apr; 187(2):612-9. PubMed ID: 1312271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary ovarian insufficiency and human papilloma virus vaccines: a review of the current evidence.
    Christianson MS; Wodi P; Talaat K; Halsey N
    Am J Obstet Gynecol; 2020 Mar; 222(3):239-244. PubMed ID: 31479634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surveillance of adverse effects following vaccination and safety of immunization programs.
    Waldman EA; Luhm KR; Monteiro SA; Freitas FR
    Rev Saude Publica; 2011 Feb; 45(1):173-84. PubMed ID: 21181055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Reply to the letter on the cost-effectiveness of human papillomavirus in Punjab further distorts the scientific record.
    Suman V; Puliyel JM
    Cancer; 2018 Mar; 124(5):1085. PubMed ID: 29165797
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply to The Reply to the letter on the cost-effectiveness of human papillomavirus in Punjab further distorts the scientific record.
    Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
    Cancer; 2018 Mar; 124(5):1085-1086. PubMed ID: 29323704
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.